Archive

Obese women have worse menopause symptoms and get less relief from hormone therapy

Written by | 28 Sep 2023

Obesity has already been associated with a number of adverse health conditions and can interfere with a person’s quality of life. A new study suggests that, in addition […]

Obesity experts spotlight safety gap in clinical trials and drug labeling for people with obesity

Written by | 12 Sep 2023

A new opinion piece published in Health Affairs Forefront raises questions around current approaches to assess drug safety and effectiveness in people with obesity. The article sheds light on how […]

New study reveals the most common form of arthritis, osteoarthritis, affects 15% of the global population over the age of 30

Written by | 26 Aug 2023

A new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and […]

Pharmacy-led obesity management with GLP agonists

Written by | 21 Jun 2023

Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short […]

Offering the best weight-loss service for patients

Written by | 20 Jun 2023

People seeking semaglutide for weight management from a pharmacy-led service need to feel assured that the service is ethical and legal and has the best interests of the […]

How to provide semaglutide for ethical weight-loss

Written by | 19 Jun 2023

Taking time to understand a patient’s weight loss goals and checking their medical history to ensure there are no underlying problems that may need onward referral are both […]

Semaglutide: what you need to know about online supply and effective use

Written by | 18 Jun 2023

Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the […]

Wegovy or Ozempic – does it matter?

Written by | 17 Jun 2023

Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist […]

Semaglutide and how it makes you want to eat less

Written by | 16 Jun 2023

Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has […]

Promoting lower-calorie options on delivery apps could help users select healthier options, randomized trials find

Written by | 22 May 2023

Simple initiatives to help people select lower-calorie options when ordering takeaways in delivery apps could help tackle the obesity epidemic, suggest three randomised trials being presented at this […]

Established cardiovascular disease in people living with overweight or obesity associated with more illness, death and medical costs than obesity alone, UK study in over 420,000 adults finds

Written by | 18 May 2023

Adults at high cardiovascular risk and living with overweight or obesity [1] experience a higher number of cardiovascular events (such as heart attack and stroke), are at greater […]

Latest UK data shows rising age, rates of obesity and comorbidity in surgical patients requiring anaesthesia, increasing the pressure on the already overloaded NHS

Written by | 5 Mar 2023

Snapshot survey data from the 7th National Audit Project of the Royal College of Anaesthetists (NAP7) published in Anaesthesia (a journal of the Association of Anaesthetists) reveals an extremely worrying picture […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.